Organization (Industry)
Rhythm Pharmaceuticals, Inc.
ClinicalTrials.gov lists Rhythm Pharmaceuticals, Inc. as lead sponsor of 29 trials. It has 48 active development programs and 3 approved assets.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials started per year with this organization as sponsor or collaborator, 1990 onward. The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.
2026 is partial: 0 registered with a 2026 start date. The dashed outline is the pace from the 0 registered with a start date through September, planned starts included, not adjusted; not a forecast. No forecast is made for this organization: it averages 2.8 trial starts a year over the five years to September, under the 5 a year the method needs.
This page covers Rhythm Pharmaceuticals, Inc.: 29 lead-sponsored trials and 4 legal-entity registrations.
Related companies are recorded in the same corporate group by GLEIF, ROR or a curator but are not grouped here; they are listed below with their own counts and are not included in the figures above.
Disease areas (23)
Shown in this order: most trials first.
| Disease area | Trials |
|---|---|
| Obesity | 21 |
| Hypogonadism | 7 |
| Sexual Infantilism | 7 |
| Bardet-Biedl Syndrome | 6 |
| Hyperphagia | 6 |
Showing 5 of 23 disease areas.
Trials by start year as sponsor or collaborator (14)
Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Show the table of trials by start year as sponsor or collaborator
| Year | Trials started |
|---|---|
| 2025 | 3 |
| 2024 | 5 |
| 2023 | 2 |
| 2022 | 1 |
| 2021 | 5 |
| 2020 | 1 |
| 2019 | 1 |
| 2018 | 4 |
| 2017 | 3 |
| 2016 | 1 |
Showing 10 of 14 years.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
Active development programs (48)
Shown in this order: max phase, then active trials.
| Drug | Disease area | Max phase | Trials |
|---|---|---|---|
| Setmelanotide | Hypogonadism | Phase 3 | 4 |
| Setmelanotide | Sexual Infantilism | Phase 3 | 4 |
| Setmelanotide | Obesity | Phase 3 | 12 |
| Setmelanotide | Hyperphagia | Phase 3 | 3 |
| Setmelanotide | Oculomotor Nerve Diseases | Phase 3 | 1 |
Showing 5 of 48 active programs.
Approved assets (3)
Shown in this order: max phase first.
| Drug | Trials |
|---|---|
| Setmelanotide | 19 |
| Moxifloxacin | 1 |
| RM-493 | 2 |
Sponsor delivery record (1)
Enrollment hit target: the share of this sponsor's lead-sponsored trials whose actual enrollment reached the planned enrollment. On time: the share whose actual primary completion date was no later than the planned date. Each share counts only trials where we observed an estimated figure before the actual one, and n is that number of trials. Below 5 trials the count is shown as a fraction, not a percentage.
| Enrollment | Timeline |
|---|---|
| 58% hit target (n=19) | 28% on time (n=18) |
Journals published in (17)
Shown in this order: most published in first.
| Journal | Publications |
|---|---|
| The lancet. Diabetes & endocrinology | 4 |
| The Journal of clinical endocrinology and metabolism | 3 |
| Orphanet journal of rare diseases | 2 |
| Advances in therapy | 1 |
| American journal of human genetics | 1 |
Showing 5 of 17 journals.
US granted patents (1)
Patents are not classified by disease area in the source, so this is the organization's overall portfolio, not a split by disease.
| US patents granted | Granted in the last 5 years | Most recent grant |
|---|---|---|
| 18 | 7 | 2025-07-15 |
SEC-reported annual financials (11)
Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.
| Fiscal year | Revenue (USD) | Net income (USD) | R&D (USD) |
|---|---|---|---|
| 2025 | 189,757,000 | -196,539,000 | 167,340,000 |
| 2024 | 130,126,000 | -260,602,000 | 237,957,000 |
| 2023 | 77,428,000 | -184,678,000 | 134,951,000 |
| 2022 | 23,638,000 | -181,119,000 | 108,630,000 |
| 2021 | 3,154,000 | -69,612,000 | 104,128,000 |
| 2020 | not reported | -133,996,000 | 90,450,000 |
| 2019 | not reported | -140,729,000 | 109,450,000 |
| 2018 | 0 | -74,064,000 | 50,337,000 |
| 2017 | 0 | -33,709,000 | 22,894,000 |
| 2016 | 0 | not reported | 19,594,000 |
Showing 10 of 11 fiscal years.
Financing and grant events (28)
Shown in this order: most recent first.
| Date | Round type | Amount (USD) | Source |
|---|---|---|---|
| 2026-02-26 | Follow-on offering | 299,714,486 | Edgar offerings |
| 2025-07-10 | Follow-on offering | 201,249,995 | Edgar offerings |
| 2025-07-09 | Other financing | not disclosed | Edgar offerings |
| 2025-07-09 | Public offering | not disclosed | Sec extracted |
| 2025-04-07 | Other financing | not disclosed | Sec extracted |
Showing 5 of 28 events.
FDA inspection record (1)
| Latest classification | Inspections |
|---|---|
| NAI | 2 |
Climate targets, as filed (1)
| Reporting year | Net-zero target |
|---|---|
| 2025 | not disclosed |
Workforce and board diversity, as filed (1)
| Reporting year | Workforce % women | Board % women |
|---|---|---|
| 2025 | not disclosed | not disclosed |
Organization relationships (2)
Shown in this order: most evidence first.
| Related organization | Relationship | Evidence |
|---|---|---|
| Tom Hühne | Co sponsors trial with | 1 |
| Rolfs Consulting und Verwaltungs-GmbH (RCV) | Co sponsors trial with | 1 |
Latest dated events (83)
Shown in this order: newest first.
| Date | Event | Source |
|---|---|---|
| 2026-03-20 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026-03-20 | PDUFA decision date | Regulatory decision dates extracted from SEC filings |
| 2026-02-26 | Follow-on offering | Funding rounds and grants (NIH RePORTER + SEC EDGAR) |
| 2025-11-10 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
| 2025-09-23 | Trial started | Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI)) |
Showing 5 of 83 events.
Biomarker capability evidence (139)
Shown in this order: tier desc, then gene symbol.
| Gene | Role | Evidence |
|---|---|---|
| BBS1 | Trial sponsor | Named in trial inclusion criteria |
| BBS2 | Trial sponsor | Named in trial inclusion criteria |
| CPE | Trial sponsor | Named in trial inclusion criteria |
| LEP | Trial sponsor | Named in trial inclusion criteria |
| LEPR | Trial sponsor | Named in trial inclusion criteria |
Showing 5 of 139 evidence rows.
Not on this page
Checked, with nothing recorded for this organization: companies grouped under this page, fda warning letters, fda untitled letters, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.